Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for TScan Therapeutics, Inc. Common Stock (TCRX).
- Disclosed ownership: 1.8%.
- Date of event: 30 Jun 2025.
BlackRock, Inc. - 30 Jun 2025 SCHEDULE 13G/A Report for TScan Therapeutics, Inc. Common Stock (TCRX)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- TCRX
- Shares outstanding
- 53,242,944 shares
- Disclosed Ownership
- 958,373 shares
- Ownership
- 1.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 16 Jul 2025, 19:02:18 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 24 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 1.8% ownership in TScan Therapeutics, Inc. Common Stock (TCRX) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 24 Apr 2025.
- Current filing was accepted on 16 Jul 2025, 19:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 1.8% | 958,373 | 955,843 | 0 | Spencer Fleming | Managing Director |